OXiGENE, Inc heute mit fast 70 % im PLUS - 500 Beiträge pro Seite

[js200]

1:08pm ET
3.00
1.21 (67.59%)
Day`s Range: 2.08 - 3.20
Day`s Volume: 287,450
Avg. Volume: 0


JS200

[meislo]

Oxigene Says OXi8007 Data Shows Tumor Growth Control
Thursday May 1, 11:42 am ET


WATERTOWN, Mass. (Dow Jones)--Oxigene Inc. plans to present tumor- controlling results in mice treated with its new vascular targeting agent OXi8007 at a conference in Florida Monday.
In a press release Thursday, the company said results of the preclinical compound OXi8007 in tumors implanted in mice and in normal tissue showed that the drug triggered a more than 95% reduction in tumor blood flow at a dose of 100 mg/kg. At doses above 250 mg/kg, tumor growth was completely repressed, Oxigene said.

The company noted there was an absence of toxicity, even at high doses.

Reached later, an Oxigene spokesman said the company expects to go to human trial with Oxi8007 in about 18 months

[meislo]

OXiGENE Announces Discovery of New Vascular Targeting Agent
Thursday May 1, 8:02 am ET
OXi8007 Exhibits Wide Therapeutic Window in Controlling Tumor Growth in Pre-clinical Cancer Model


WATERTOWN, Mass.--(BUSINESS WIRE)--May 1, 2003--Broadening its arsenal of novel Vascular Targeting Agents (VTAs) designed to destroy solid tumors by disrupting their blood flow while leaving healthy cells intact, OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced plans for the presentation of the first scientific paper on its new drug candidate, OXi8007.
ADVERTISEMENT


In a paper scheduled to be delivered on Monday, May 5th at the Tumor Microenvironment Workshop`s "Eighth Annual International Meeting on the Tumor Microenvironment and its Impact on Cancer Therapies" conference in Miami Beach, Florida, researchers will describe in vitro and in vivo experiments conducted with OXi8007. "The vascular shutdown induced by administration of OXi8007 resulted in extensive tumor cell death 24 hours following treatment, which translated into a significant effect on tumor growth," said Kevin G. Pinney, associate professor of chemistry at Baylor University, OXiGENE`s academic research partner.

The vascular effects of OXi8007 were evaluated in tumors implanted in SCID (severe combined immunodeficient) mice and in normal tissue. At a dose of 100 mg/kg, the compound triggered a more than 95 percent reduction in tumor blood flow. At doses above 250 mg/kg, tumor growth was completely repressed, researchers said.

"The profile of OXi8007 is unique from the other compounds that we have in the pipeline," said Dai Chaplin, Ph.D., OXiGENE`s chief scientific officer and head of research and development. "With our lead compound, Combretastatin A4 Prodrug, (CA4P), in Phase II clinical trials, OXi4503 expected to enter the clinic early next year and OXi6197 in pre-clinical development, OXi8007 complements a strong drug development portfolio."

The molecular structure of OXi8007 is distinct from OXiGENE`s Combretastatin family of tumor-starving compounds (CA4P and OXi4503) and from its OXi6197 anti-tumor agent. OXi8007 is the subject of a pending patent application that, if issued, would provide OXiGENE with a means of protecting the technology in the United States and major market countries worldwide.

"Identification of OXi8007 as a lead preclinical development candidate from another novel series of compounds underscores our successful drug discovery initiatives," said Fred Driscoll, the Company`s president and CEO. "Although the compound is at an early stage of development, we are encouraged by the fact that, thus far, OXi8007 has exhibited a wide therapeutic window and an absence of toxicity, even at high doses."

About OXiGENE

OXiGENE is the world leader in the development of novel biopharmaceutical compounds called Vascular Targeting Agents (VTAs), which are designed to block the flow of blood that supplies solid cancer tumors and other abnormal vasculature, while leaving healthy cells intact. The Company`s VTAs may have application in the treatment of certain forms of ocular disease and other conditions. OXiGENE`s lead compound, Combretastatin A4 Prodrug, has advanced into Phase II and combination clinical trials in cancer patients in the United States and Europe. For more information about OXiGENE, visit www.oxigene.com.

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: the planned presentation of a scientific paper on OXi8007; the therapeutic window and toxicity profile of OXi8007; the pending patent application regarding OXi8007; the expectation that OXi4503 will enter Phase I clinical trials next year; the ability of the Company`s vascular targeting agents to block the flow of blood that supplies solid cancer tumors and other abnormal vasculature, while leaving healthy cells intact; the applicability of the Company`s VTAs to certain forms of ocular disease and other conditions; the ability of the Company`s drugs to enhance the effectiveness of traditional cancer treatments; and the introduction of innovative therapies that attack cancer and other diseases. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to: the early stage of product development; the ability to secure necessary patents; uncertainties as to the future success of ongoing and planned clinical trials; and the unproven safety and efficacy of products under development. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements are contained in OXiGENE`s reports to the Securities and Exchange Commission, including OXiGENE`s 10-Q, 8-K and 10-K reports. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise.

[js200]

05/01/2003 (10:58 ET) VOLUME(+): OXGN Volume 180% > 20-adsv, Stock +22.91% - Knobias
05/01/2003 (08:48 ET) OXGN Reports on OXi8007 an Agent for Vascular Targeting - Knobias
05/01/2003 (08:02 ET) OXiGENE Announces Discovery of New Vascular Targeting Agent; OXi8007 Exhibits Wide Therapeutic Window in Controlling Tumor Growth in Pre-clinical Cancer Model - Business Wire
05/01/2003 (02:01 ET) OXiGENE ANNOUNCES DISCOVERY OF NEW VASCULAR TARGETING AGENT - Hugin AS
04/30/2003 (17:29 ET) New 10-K/A just released for OXGN - Edgar

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


05/01/2003 (10:58 ET) VOLUME(+): OXGN Volume 180% > 20-adsv, Stock +22.91% - Knobias



05/01/2003 (08:48 ET) OXGN Reports on OXi8007 an Agent for Vascular Targeting - Knobias



05/01/2003 (08:02 ET) OXiGENE Announces Discovery of New Vascular Targeting Agent; OXi8007 Exhibits Wide Therapeutic Window in Controlling Tumor Growth in Pre-clinical Cancer Model - Business Wire



05/01/2003 (02:01 ET) OXiGENE ANNOUNCES DISCOVERY OF NEW VASCULAR TARGETING AGENT - Hugin AS



04/30/2003 (17:29 ET) New 10-K/A just released for OXGN - Edgar



04/24/2003 (13:11 ET) VOLUME(+): OXGN Volume 412% > 20-adsv, Stock +10.06% - Knobias



04/17/2003 (15:45 ET) New 4 just released for OXGN - Edgar



04/11/2003 (08:19 ET) OXiGENE: CONFERENCE CALL NOTICE - Hugin AS



04/11/2003 (08:13 ET) OXiGENE Invites Public to Listen to Internet Broadcast of First-quarter 2003 Financial Results Conference Call - Hugin AS



04/11/2003 (08:01 ET) OXiGENE Invites Public to Listen to Internet Broadcast of First-quarter 2003 Financial Results Conference Call - Business Wire

JS200

[Ariminios]

verdammte scheisse, und ichhab vorgestern verkauft, fuck

[meislo]

WIE WIIST DU DENN VORGESTERN VERKAUFT HABEN WENN ÜBERHAUPT KEINE AKTIEN GEHANDELT WURDEN??
ÜB WEITER IM SANDKASTEN DAS BEKOMMT DIR BESSER

[oski]

*6
Hast vielleicht in Armenien verkauft auf dem Schwarzmarkt

[Megapol]

@#7/#8

Habt Ihr zwei "Experten" schonmal daran gedacht, dass man vielleicht in den USA verkauft hat

Also, nichts mit Schwarmarkt und mit der Sandkiste sollten sich lieber zwei andere beschäftigen

[js200]

Umsätze waren vorhanden jeden Tag in den letzten beiden Monaten in USA

Nur wenig aber trotzdem

JS200

[meislo]

#9

Wer es glaubt wird selig

[Ariminios]

#7 und #8

Was seid Ihr denn fuer Lemminge? #9 hat ganz recht.

Und wie kommt ihr ueberhaupt dazu mir zu unterstellen, ich wuerde luegen? Ich hab den scheiss mit Verlust einen zwei Tage vor der Explosion verkauft, as ob das irgendwie toll ist. Das einzig gute ist, ich kannte die Aktie schon vor euch Lemmingen!

Lest und lernt:

http://aktienboard.com/vb/showthread.php?s=e9e84c1302d6f6595…

[Ariminios]

Wenn du das post auf dem link in #12 angeguckt hast, bist ja dann jetzt selig...

Bin ich jetzt ein Held fuer Dich, weil ich in Amerika (ohoo!) handeln kann?

[js200]

OXiGENE Reports Operational Highlights and Financial Results For the First Quarter of 2003
via COMTEX

May 2, 2003

WATERTOWN, Mass., May 2, 2003 (BUSINESS WIRE) --

Patient enrollment completed in Phase Ib Cancer Trial

OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target the vascular structure of solid tumors, today reported operational highlights and financial results for the quarter ended March 31, 2003.

Recent operational highlights include: -- Issuance of a U.S. patent covering the Company`s `prodrug strategy,`which encompasses tubulin-binding compounds to selectively target and destroy aberrant blood vessels without damaging the surrounding healthy tissue. U.S. Patent No. 6,538,038 covers the use of multiple Vascular Targeting Agents (VTAs) to treat cancer, macular degeneration and other illnesses characterized by the formation of abnormal blood vessels. The Company currently has 17 U.S. patent applications pending and numerous foreign applications pending related to its vascular targeting technology. -- Initiation of a Phase I/II clinical trial of its lead VTA, Combretastatin A4 Prodrug (CA4P), and radiotherapy in patients with advanced malignancies of the lung, head &neck and prostate. The trial is being conducted at Mount Vernon Hospital in London. -- Discovery of a new vascular targeting candidate, OXi8007, emanating from the Company`s drug discovery program. First-quarter 2003 Financial Results
Total revenue for the first quarter of 2003 was approximately $69,000 compared with approximately $79,000 for the same period in 2002. OXiGENE`s GAAP (Generally Accepted Accounting Principles) net loss for the first quarter of 2003 was approximately $1.5 million, or $0.12 per basic and diluted share, versus a GAAP net loss of approximately $4.2 million, or $0.35 per basic and diluted share, in the first quarter of 2002. The GAAP net loss for the first quarter of 2002 includes a one-time non-cash charge of $2.3 million related to a stock award program and a non-recurring gain of $1.3 million related to the Company`s sale of its interest in the ARCUS LLC joint venture to Peregrine Pharmaceuticals, Inc. Excluding these non-recurring items, the net loss on a non-GAAP basis for the first quarter of 2002 would have been approximately $3.2 million. Therefore, on a non-GAAP basis the $1.5 million net loss in the first quarter of 2003 represents an improvement of $1.7 million, or 53 percent, from the comparable period in 2002.

Management is furnishing a non-GAAP measure in the presentation of the Company`s financial results to provide a consistent comparison of historical operating performance. Management believes this measure provides a useful comparison because it excludes certain items, such as stock compensation expenses and non-operating gains, which do not necessarily reflect the Company`s results from ongoing operating activities.

OXiGENE ended the first quarter of 2003 with $10.0 million in cash and marketable securities compared with $11.8 million at December 31, 2002.

`The improvement in OXiGENE`s bottom line in the first quarter of 2003 is a direct result of our drug development strategy over the past year,`said President and Chief Executive Officer Fred Driscoll. `Focusing the Company exclusively on vascular targeting has enabled us to implement a number of cost-reduction initiatives. These measures, in turn, have helped to significantly reduce our net loss in the first quarter of 2003 compared with the first quarter of 2002. We have projected a $5 million to $6 million net loss for 2003 and, on an annualized basis, our first-quarter financial results put us on pace to realize that result.

`While we have sought to aggressively lower costs over the past several quarters, we have done so without sacrificing clinical development momentum,`Driscoll continued. `Since mid-2002, CA4P has entered three concurrent clinical trials and our discovery program has produced two new compounds -- OXi6197 and OXi8007. In addition, we have made steady progress in our efforts to move OXi4503 into the clinic.`

Update on Clinical Trials

In addition to the Phase I/II study at Mount Vernon Hospital in London, CA4P is involved in two other cancer trials. At the Ireland Cancer Center at University Hospitals of Cleveland, the compound is undergoing a Phase II trial as a single agent in patients with advanced anaplastic thyroid cancer. CA4P also is being tested at the University of Pennsylvania`s Presbyterian Medical Center, in a Phase Ib combination study with the chemotherapy drug Carboplatin in patients with various advanced solid tumors. While patients in the study continue to receive therapy, enrollment has concluded.

`The primary aims of the Phase Ib trial were to establish the maximum tolerated dose of the combination and the recommended Phase II dose when CA4P is administered as a 10-minute intravenous infusion,` said Dai Chaplin, Ph.D., OXiGENE`s chief scientific officer and head of research and development. `Additionally, the study was intended to assess the toxicity and safety profile of the combination and collect data on possible anti-tumor effects. The objectives have been achieved and the data gathered from this study will be invaluable as we move CA4P forward. Indeed, based on the data already obtained we are awaiting regulatory approval to launch an advanced clinical trial, in combination with conventional treatment, targeted at a specific and prevalent tumor type.`

Second-generation VTAs

Pre-clinical development of OXi4503 and OXi6197, OXiGENE`s second-generation VTAs, remains on schedule. The peer-reviewed journal Anticancer Research has indicated that it is preparing to publish a research paper exploring the effects on blood-flow shutdown and tumor volume of OXi4503 and CA4P. Work also continues on OXi6197. The investigational compound is being evaluated by the Drug Development Group of the National Cancer Institute (NCI), which has seen anti-tumor effects in initial rounds of in vivo studies in animals. The NCI has agreed to perform additional in vivo tests this year.

This week, OXiGENE introduced its fourth VTA, OXi8007, whose molecular structure is distinct from the Combretastatin family of compounds as well as OXi6197. The new compound, which in pre-clinical studies has demonstrated a wide therapeutic window and absence of toxicity at high doses, is the subject of a scientific paper scheduled to be presented next Monday, May 5, at a Florida conference on emerging cancer therapies.

`Discovery of new vascular targeting candidates remains an important element in our overall strategic plan, and OXi8007 is the most recent example of the fruitful relationship between OXiGENE and our academic research partners, Baylor University in Texas and the University of Lund in Sweden,`Driscoll said.

Business Outlook

Commenting on the Company`s outlook for the remainder of 2003, Driscoll said, `Our plan is to continue to identify clinical development opportunities for CA4P, both in new indications and new therapeutic combinations. Over the next several months, we expect to move CA4P into advanced trials with chemotherapy. We also plan to announce the location of a Phase I/II trial in wet age-related macular degeneration. In addition, we are engaged in discussions with potential CA4P licensing partners in both oncology and ophthalmology.`

Company to Host Conference Call

OXiGENE will host a conference call with investors at 10:00 a.m. ET today to review its first quarter 2003 financial results and provide a business update. Callers in the U.S. can participate by dialing [phone], while international callers should dial [phone]. For a live and archived audio Webcast of the call, go to www.oxigene.com/investor/confcalls.asp

A telephone rebroadcast will be available two hours after the call until noon ET May 4, 2003. To hear this replay, dial [phone] (U.S.) or [phone] (international) and use passcode 21135424.

About OXiGENE

OXiGENE is the world leader in the development of novel biopharmaceutical compounds called Vascular Targeting Agents (VTAs), which are designed to block the flow of blood that supplies solid cancer tumors and other abnormal vasculature, while leaving healthy cells intact. The Company`s VTAs may have application in the treatment of certain forms of ocular disease and other conditions. OXiGENE`s lead compound, Combretastatin A4 Prodrug, has advanced into Phase II and combination clinical trials in cancer patients in the United States and Europe. For more information about OXiGENE, visit www.oxigene.com.

Safe Harbor Statement

This news release contains `forward-looking statements`within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: the Company`s projection of a $5 million to $6 million net loss for 2003; the Company`s ability to move OXi4503 into the clinic; the Company`s ability to successfully apply the data gathered in the Phase Ib clinical trial in further study of CA4P; OXiGENE`s ability to obtain the regulatory approval to move CA4P into an advanced trial targeted at a specific cancer indication in combination with conventional treatment; the Company`s intention to continue to identify clinical development opportunities for CA4P; OXiGENE`s plan to move CA4P into advanced clinical trials in chemotherapy; the Company`s plan to announce the location of a Phase I/II clinical trial of CA4P in wet age-related macular degeneration; and the application of the Company`s VTAs in the treatment of certain forms of ocular disease and other conditions. Any or all of the forward-looking statements in this press release may turn out to be wrong.

They can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to: the early stage of product development; the ability to secure necessary patents; uncertainties as to the future success of ongoing and planned clinical trials; and the unproven safety and efficacy of products under development. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements are contained in OXiGENE`s reports to the Securities and Exchange Commission, including OXiGENE`s 10-Q, 8-K and 10-K reports. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise.

OXiGENE, Inc. Consolidated Balance Sheet (All amounts in thousands US Dollars) March 31 December 31, Assets 2003 2002 Current Assets: (Unaudited) (Audited) Cash $1,684 $3,752 Available-for-sale marketable securities 8,306 8,078 Other current assets 43 40 Total current assets 10,033 11,870 Net property and equipment 449 487 Other assets 1,216 1,241 Total assets $11,698 $13,598 Liabilities and stockholders`equity Current Liabilities: Amount payable for license agreement - current $297 $290 Accrued expenses 1,575 1,717 Accounts payable 1,058 1,417 Total current liabilities 2,930 3,424 Amount payable under license agreement - non-current 158 154 Stockholders`equity Common stock 127 127 Additional paid-in capital 83,376 83,465 Accumulated deficit (73,089) (71,654) Notes receivable (2,098) (2,187) Other 294 269 Total stockholders`equity 8,610 10,020 Total liabilities and stockholders`equity $11,698 $13,598
OXiGENE, Inc Consolidated Statement of Operations (All amounts in thousands, 3 months 3 months except per share amounts) ended ended Mar 31, Mar 31, 2003 2002 (unaudited) Revenues: Licensing revenue $20 $- Interest income 49 79 Total revenues 69 79 Expenses: Costs relating to licensing revenue - - Amortization of license agreement 20 20 Operating expenses 1,517 5,539 Total expenses 1,537 5,559 Operating loss (1,468) (5,480) Gain on sale of Joint Venture - 1,325 Other expense, net (8) (16) Net loss $(1,476) $(4,171) Net loss per common share: Basic $(0.12) $(0.35) Diluted $(0.12) $(0.35) Shares used to compute net loss per share: Basic 12,443 11,961 Diluted 12,443 11,961
SOURCE: OXiGENE, Inc.

Sharon Merrill Associates 617/542-5300 David Calusdian (Investors) [e-mail] Scott Solomon (Media) [e-mail]

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved

JS200

[meislo]

Hallo Ariminios

Tut mir Leid für die Angiftung meinerseits. Ich entschuldige mich hiermit.

gruss meislo

[Ariminios]

Akzeptiert.Das ist ein ehrbares Wort, meislo.

[meislo]

Danke

gruss meislo

[js200]

http://www.investtech.com/nasdaq/ana/oxgn.htm

JS200

[Ariminios]

Ich hab mal den pullback gekauft, sollten schnelle 25 % bis 2.50 $ sein. Alle anderen news-Bios haben sich auch so verhalten. Zum Beispiel CRIS.

[meislo]

Hallo Arinimios

Bist Du noch drin Aktie geht ja ab wie eine Rakete + 56%


Hier die News

Oxigene in Collaboration With Cancer Research UK
Tuesday May 27, 9:56 am ET


WATERTOWN, Mass. (Dow Jones)--Cancer Research UK, in an agreement with Oxigene Inc. (NasdaqNM:OXGN - News) , will complete preclinical trials and Phase I trials of the OXi4503 cancer treatment.
ADVERTISEMENT


In a press release Tuesday, Oxigene said preclinical trials will be completed in 2003 in preparation for Phase I human trials in early 2004.

Shares of Oxigene recently traded at $4.04, up $1.24, or 44%, in the premarket session.

With the completion of OXi4503 preclinical development, Oxigene reached one of its preestablished milestones in 2003.

In a study published Tuesday, OXi4503 was shown to block the flow of blood to solid tumors implanted into mice models. Compared to normal vessels, the newly developed tumor vessels were more fragile, making them more vulnerable to vascular targeting drugs.

"Our early research suggests that OXi4503`s molecular structure delivers something of a double-barreled effect in that it not only shuts down blood flow at the core of the tumor but is then metabolized into a compound that selectively kills the remaining tumor cells at the periphery," said Dai Chaplin, Oxigene`s chief scientific officer.

Cancer Research UK, is a European cancer charity which aims to cure, treat and prevent cancer through research.

Shares of Oxigene, a biopharmaceutical company, recently traded at a new 52- week high of $4.48, up $1.68, or 60%, on Nasdaq volume of 2.1 million shares, compared with average daily volume of 44,507 shares. The stock reached its previous high of $3.20 in January and traded as low as 78 cents in December.

[meislo]

Oxigene: Aktie steigt 56 Prozent
27.05.2003 18:45:00


Die Aktie des Biotechunternehmens Oxigene Inc. gehört heute zu den größten Gewinnern an der Nasdaq. Wie das Unternehmen bekannt gab, sei eines der von ihm entwickelten Krebs-Medikamente zur letzten vorklinischen Studie zugelassen worden. Die ersten Untersuchungen mit Menschen sollen Anfang 2004 durchgeführt werden.
Im Falle einer Markt-Zulassung würde dies für das Unternehmen wahrscheinlich enorme Umsätze mit diesem Produkt bedeuten.

Die Aktie notierte zuletzt bei 4,38 Dollar mit einem Plus von 56,4 Prozent. Dies entspricht einer Marktkapitalisierung von 55,5 Mio. Dollar.


-red- / -red-

[Ariminios]

Nein! Ich hatte natuerlich zuwenig Geduld und hab ein paar Tage spaeter den Trade aus #19 wieder aufgegeben!

[meislo]

Dumm gelaufen und das bei diesem Hype

Bei mir läuft es im Moment auch nicht so gut.Meine grösste Position im Biotechsektor liegt heute sogar im Minus und das obwohl der NASDAG-Biotech-index mit 5 % im PLus steht

Au Backe

gruss meislo

[Ariminios]

Qiagen? Sonst seh ich garnix im minus.

[meislo]

Geron -1,5%



http://finance.yahoo.com/q?d=t&s=GERN

gruss
meislo

[Ariminios]

wow, das ist aber auch ein volatiles Stueck GERN

Finde aber der chart sieht recht bullish aus.

[js200]

http://www.investtech.com/nasdaq/ana/gern.htm

JS200

[js200]

.
http://www.investtech.com/nasdaq/ana/oxgn.htm

JS200

[js200]

Wall Street News Alert Announces Investment Opinion: Microsoft Calling
via COMTEX

May 28, 2003

WESTON, FL, May. 28, 2003 (MARKET WIRE via COMTEX) --

Keep your eye on Dreamfield Holdings, Inc. (OTC: DRMH). Yesterday after the markets closed, the company announced the continuation of its aggressive business style, by adding another company to their growing portfolio in the acquisition of SARSTech.com, a new Connecticut-based `dot com.`SARSTech.com will offer up to the minute news, SARS protection and prevention products, such as 3M respirator masks, both at the retail and wholesale levels. Last, the portal will provide key information and `Question &Answers`regarding SARS. Dreamfield Holdings now has three subsidiaries, Helicopters Unlimited Inc., Dreamfield Entertainment and newly acquired SARSTech.com. Keep Dreamfield on your radar screen as the company continues to aggressively search for new potential acquisitions with high growth potential. Other active stocks yesterday were:

OXiGENE Inc. (NASDAQ: OXGN) up 55% to $4.35 on 5.2 million shares traded, Biopure Corporation (NASDAQ: BPUR) up 21% to $6.00 on 2 million shares traded and Regeneron Pharmaceuticals (NASDAQ: REGN) up 21% to $13.62 on 3.6 million shares traded.

Market Commentary

`Ring, Ring.` `Who`s calling?` `Bill Gates` `Microsoft Bill Gates?` `You bet.`

`That`s right, not just the computer, Internet, and related software, now he is after your phone bill. Microsoft just launched its mobile phone system, starting in Sweden with a company called TeliaSonera. In a joint venture, the SPV, sound, pictures and video systems, Microsoft is now getting a piece of the advanced mobile phone market. Motorola, Samsung and Siemens are watching closely fearing that the software giant will come to dominate the operating software for these hand-held computer devices much as the software giant has done in the pc software market,`stated Sonja Rudd in Wall Street News Alert`s daily commentary continued at: www.WallStreetNewsAlert.com.

WSNA`s email alert service is free to those investors who sign up on the WSNA home page. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity and gains in their securities. The Wall Street News Alert home page has experienced over 4.7 million hits. To subscribe to this free service, visit the Wall Street News Alert home page at www.wallstreetnewsalert.com and select the `join now`button.

Verify all claims and do your own due diligence. Wall Street News Alert is a division of Wall Street Capital Funding (WSCF). WSCF profiles are not a solicitation or recommendation to buy, sell or hold securities. WSCF is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of WSCF and are subject to change without notice. The companies that are discussed in this opinion have not approved the statements made in this opinion. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended. The words `may,``would,``will,``expect,` `estimate,``anticipate,``believe,``intend,`and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company`s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. WSCF is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained in WSCF profiles is provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in WSCF profiled stocks. WSCF has been compensated by third-party shareholders on behalf of one or more of the companies mentioned in this opinion. [WSCF has received Six Hundred and Fifty Thousand free trading shares of Dreamfield Holdings, Inc. (OTC: DRMH), from a third party (XXR Consulting Inc.), for services provided including this advertisement.] WSCF may immediately sell its shares. WSCF will not advise as to when others should sell; each investor must make that decision. Market commentary provided by Sonja Rudd, CRD number 2683330.

Roy Campbell Wall Street News Alert 954-349-5813

Copyright 2003 Market Wire, All rights reserved.

JS200

[meislo]

Hallo Ariminios

Geron ist mit abstand das interessanteste und spannenste was Biotech zu bieten hat. Eine Microsoft im Biotech-bereich oder vielleicht doch nur eine Commondore. Wer weiss ? Spannend auf jedenfall!!!

siehe ThreadThread: Geron mit Hammernews!!

[Guru-Schreck]

Wednesday June 4, 7:15 am ET

OXiGENE`s Lead Cancer-Fighting Agent Receives Fast Track Designation from U.S. FDA

http://biz.yahoo.com/bw/030604/45306_1.html

[Guru-Schreck]

Jetzt bei 6$ vorbörslich.

[Ariminios]

oh nee, das gibs ja garnicht!

[meislo]

Ich sitze auch nur noch staunend vor dem PC

gruss meislo

[js200]

Na Jungs, ne tolle Leistung

4:00pm ET
7.23
3.29 (83.50%)
Day`s Range: 6.19 - 7.85
Day`s Volume: 12,197,959
Avg. Volume: 0

JS200

[hrD]

Ich beobachte Oxigne schon ene ganze weile und denke das ihr Ansatz einer der Erfolgversprechenderen der Angiogenese Spezialisten ist.
Nach den positiven Daten von DNA ist der anze Bereich immer noch "on Fire"
Neben Oxgn sollte man sich aber auch Aela (Ph § Test bei Neovastat) und Genaera (vielecht bald Phase 3 mit Squalamine) mal enauer anschauen. Der Vollständigheit halber sollte man aber auch Entremed mit Panzem und Celgene(den größten Wert aus diesem Bereich) erwähnen.
Der Krebssektor im allgemeinen und Angiogenese im speziellen sind auf die nächsten Jahre gesehen sehr vielversprechend.
Vieleicht fallen euch noch ein paar andere Angiogenese Werte ein.

[meislo]

strong buy

Press Release Source: OXiGENE, Inc.


OXiGENE Announces Combination Clinical Trial of CA4P in Patients with Advanced Ovarian Cancer
Monday June 9, 7:55 am ET
Vascular Targeting Agent will be Combined with Standard-of-Care Chemotherapeutic Regimen
Fourth Concurrent Clinical Trial of Company`s Lead Tumor-Starving Compound


WATERTOWN, Mass.--(BUSINESS WIRE)--June 9, 2003-- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) announced today that its lead Vascular Targeting Agent (VTA), Combretastatin A4 Prodrug (CA4P), will be combined with two standard-of-care chemotherapy drugs in a new clinical trial involving patients with advanced ovarian cancer.
CA4P will be studied in combination with carboplatin and paclitaxel in a Phase I/II trial that is being launched at Mount Vernon Hospital in the United Kingdom. The trial protocol has been approved by the U.K.`s health regulatory authority, the Medicines Control Agency, as well as the hospital`s Institutional Ethics Committee. The Phase I arm of the study, which will include roughly 30 patients, will assess the safety and tolerability of the combination and will establish the optimal dosing schedule. The Phase II arm, which is expected to include between 20 and 30 patients, will focus on collecting additional safety data and evaluating anti-tumor efficacy.

"While radiation, chemotherapy and surgery have enabled medical professionals to manage cancer more effectively, the fact remains that many solid tumors remain incurable," said the study`s principal investigator, Gordon Rustin, M.D., director of the Department of Medical Oncology at Mount Vernon Hospital. "This trial presents an opportunity to study the most clinically advanced Vascular Targeting Agent - CA4P - with two drugs that are considered the established standard of chemotherapy treatment in ovarian cancer."

"Our drug development program continues to build momentum," said Fred Driscoll, OXiGENE`s president and CEO. "Over the past 12 months, CA4P has progressed into four clinical trials in five distinct tumor types - anaplastic thyroid, head & neck, lung, prostate and, now, ovarian - which are expected to account for more than 445,000 new cancer cases in the U.S. in 2003. The breadth of clinical evaluation of CA4P truly reflects the level of interest in the compound as an anti-cancer therapy."

Ovarian cancer ranks second in the number of new cases per year among the gynecologic cancers, according to the American Cancer Society (ACS). However, ovarian cancer causes more deaths per year than any other cancer of the female reproductive system. The ACS estimates that, in 2003, 14,300 ovarian cancer deaths will occur in the U.S. and another 25,400 women will be diagnosed with the disease.

OXiGENE announced last week that the U.S. Food and Drug Administration (FDA) granted "fast track" designation to CA4P for the treatment of advanced anaplastic thyroid cancer (ATC). CA4P currently is being evaluated in a Phase II study of patients with this disease.

In addition to the Phase I/II trial announced today and the Phase II study of patients with ATC, CA4P is being evaluated in a Phase I/II combination study with radiotherapy in patients with malignancies of the lung, head & neck and prostate; and a Phase Ib combination study with carboplatin in patients with various solid tumors. Although the carboplatin trial is ongoing and patients are still receiving therapy, there is no further patient accrual as the study objectives have been achieved. The data already obtained from the carboplatin study is being used in the design of this new, more advanced trial combining CA4P with carboplatin and paclitaxel.

CA4P is the water-soluble prodrug of Combretastatin A4, a compound isolated from the African bush willow Combretum Caffrum. CA4P is designed to damage and destroy solid tumors by impeding the flow of blood that carries the oxygen and nutrients these tumors need to grow and thrive. Research suggests that CA4P works by disrupting the intricate network of endothelial cells lining the tumor blood vessels, in essence killing the tumor from the inside. In Phase I trials, CA4P demonstrated biological effect with a complete patient response in anaplastic thyroid carcinoma and a partial response in fibrosarcoma. Several other Phase I patients with colon, medullary thyroid and pancreatic cancer saw prolonged periods of disease stabilization.

About OXiGENE

OXiGENE is the world leader in the development of novel biopharmaceutical compounds called vascular targeting agents (VTAs), which are designed to block the flow of blood that supplies solid cancer tumors and other abnormal vasculature, while leaving healthy cells intact. The Company`s VTAs may have application in the treatment of certain forms of ocular disease and other conditions. OXiGENE`s lead VTA, Combretastatin A4 Prodrug, has advanced into Phase II and combination clinical trials in cancer patients in the United States and Europe. Three other OXiGENE VTAs, OXi4503, OXi6197 and OXi8007, are in pre-clinical development. For more information about OXiGENE, visit www.oxigene.com.

Safe Harbor Statement

This news release about the Phase I/II combination trial of CA4P, carboplatin and paclitaxel contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: the number of patients expected to be enrolled in each arm of the study; the study`s objectives; the expected number of new cases of lung, prostate, head & neck and ovarian cancer in the U.S. in 2003; the ability of OXiGENE`s vascular targeting compounds to enhance the effectiveness of traditional cancer treatments; and the introduction of innovative therapies to attack cancer and other diseases. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to: the early stage of product development; the ability to secure necessary patents; uncertainties as to the future success of ongoing and planned clinical trials; and the unproven safety and efficacy of products under development. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements are contained in OXiGENE`s reports to the Securities and Exchange Commission, including OXiGENE`s 10-Q, 8-K and 10-K reports. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise.

[meislo]

Rakete pur

http://finance.yahoo.com/q?s=OXGN&d=e

[meislo]

Dow Jones Business News
Oxigene Drug to be Used With Others in New UK Study
Monday June 9, 10:10 am ET


WATERTOWN, Mass. (Dow Jones)--Oxigene Inc.`s vascular targeting agent, Combretastatin A4 Prodrug, or CA4P, will be combined with two chemotherapy drugs in a new clinical trial involving patients with advanced ovarian cancer.
ADVERTISEMENT


In a press release Monday, the biopharmaceutical company said CA4P will be studied in combination with carboplatin and paclitaxel in a Phase I/II trial that is being launched at Mount Vernon Hospital in the United Kingdom.

The trial protocol has been approved by the U.K.`s health regulatory authority, the Medicines Control Agency, as well as the hospital`s Institutional Ethics Committee.

The Phase I arm of the study, which will include roughly 30 patients, will assess the safety and tolerability of the combination and will establish the optimal dosing schedule. The Phase II arm, which is expected to include between 20 and 30 patients, will focus on collecting additional safety data and evaluating anti-tumor efficacy.

Last week, shares of Oxigene reached a new 52-week high after federal regulators gave CA4P fast-track status for the treatment of thyroid cancer.

The fast-track approval, from the Food and Drug Administration (News - Websites), means the agency will speed up its evaluation of the compound. The decision was based on the urgent need for treatments of anaplastic thyroid cancer, for which there is no current treatment.

Shares of Oxigene recently traded up $1.31, or 15.4%, to $9.79, another 52- week high, on volume of 1.3 million shares, compared to daily average volume of 468,000 shares

[meislo]

In der Spitze 100 % alleine Heute

NEW YORK, June 9 (Reuters) - Shares of OxiGENE Inc. (NasdaqNM:OXGN - News; Stockholm:OXGN.ST - News) jumped more than 40 percent on Monday after it said it will begin an early-stage trial of its experimental drug in patients with advanced ovarian cancer.
The company said last week that the drug, known as Combretastatin A4 Prodrug, will receive an accelerated review by U.S. regulators as a treatment for thyroid cancer.

The drug is designed to cut off blood to tumors in a process known as anti-angiogenesis. Drugs based on this technique are receiving greater attention since Genentech Inc. said earlier this month its drug Avastin extended life in colon cancer patients. Avastin also works by starving tumors of blood.

The early-stage trial of OxiGENE`s drug in ovarian cancer will take place at Mount Vernon Hospital in the united Kingdom.

Shares of OxiGENE, which is based in Watertown, Massachusetts, rose $3.71 to $12.19 in midmorning trading on Nasdaq.

[Ariminios]

hehe bei Aktienboard gibt es so ein Pick of the week Spiel, und einer hat letzte Woche OXGN short genommen, hat natuerlich 100 % miese eingesteckt. Diese Woche meinte er, jau also jetzt erst recht! Wieder 100 % miese

Also es ist wirklich unglaublich, wenn ich dran denke, dass ich erst vor kurzem zu 1.60 vertickt hab, dann weiss ich, wie es ist, bei 1000 % unfaehig zu sein mitzuverdienen!

[meislo]

Gegen ein Fast Track zu shorten und das in so einer Zeit ist schon dumm gelaufen für ihn. Nächste Woche auf ein neues

[js200]

4:00pm ET
13.80
5.32 (62.73%)
Day`s Range: 9.31 - 19.40
Day`s Volume: 27,745,348
Avg. Volume: 0

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


06/10/2003 (10:06 ET) VOLUME(-): OXGN Volume 10% > 20-adsv, Stock -5.07% - Knobias



06/10/2003 (09:58 ET) Oxigene announces 1.5 mln share private placement - AFX News Asia



06/10/2003 (09:58 ET) Oxigene announces 1.5 mln share private placement - AFX News Europe



06/10/2003 (09:58 ET) Oxigene announces 1.5 mln share private placement - AFX News UK



06/10/2003 (09:31 ET) OXiGENE Announces $15 Million Private Placement of Common Stock - Business Wire



06/10/2003 (08:49 ET) Wall Street News Alert Announces Investment Opinion: Moneymaker Hits the Jackpot! - Internet Wire



06/10/2003 (08:26 ET) Capital Research Group Announces Investment Opinion: Latest Advance in Equities! - Internet Wire



06/10/2003 (08:18 ET) Oxigene climbs on initiation of new trial - Datamonitor



06/10/2003 (06:52 ET) MEDIA: Today`s IBD Mentions OXGN - Knobias



06/09/2003 (16:41 ET) Biotech stocks, Genentech close lower - UPDATE 4 - AFX News Asia



06/09/2003 (16:41 ET) Biotech stocks, Genentech close lower - UPDATE 4 - AFX News Europe



06/09/2003 (16:41 ET) Biotech stocks, Genentech close lower - UPDATE 4 - AFX News UK



06/09/2003 (16:04 ET) Biotech stocks, Genentech weaken - UPDATE 3 - AFX News Asia



06/09/2003 (16:04 ET) Biotech stocks, Genentech weaken - UPDATE 3 - AFX News Europe



06/09/2003 (16:04 ET) Biotech stocks, Genentech weaken - UPDATE 3 - AFX News UK



06/09/2003 (15:58 ET) Biotech stocks, Genentech weaken - UPDATE 2 - AFX News Asia



06/09/2003 (15:58 ET) Biotech stocks, Genentech weaken - UPDATE 2 - AFX News Europe



06/09/2003 (15:58 ET) Biotech stocks, Genentech weaken - UPDATE 2 - AFX News UK



06/09/2003 (15:30 ET) Biotech stocks, Genentech weaken - UPDATE 1 - AFX News Asia



06/09/2003 (15:30 ET) Biotech stocks, Genentech weaken - UPDATE 1 - AFX News Europe



06/09/2003 (15:30 ET) Biotech stocks, Genentech weaken - UPDATE 1 - AFX News UK



06/09/2003 (15:23 ET) Schaeffer`s `Herd` on the Street Features Apple Computer, Freddie Mac, and OXiGENE: AAPL, FRE, OXGN - PR Newswire



06/09/2003 (13:53 ET) SECTOR(HCR): First Albany Comments on Biotech Industry - Knobias



06/09/2003 (12:03 ET) SECTOR(HCR): Biotechs Down; OXGN, ENMD, GERN, PPHM Up - Knobias



06/09/2003 (11:41 ET) MOVER(+): PPHM Higher on Coattails of OXGN Announcement - Knobias


JS200

[js200]

OXiGENE to Present at BIO 2003 Annual Convention; June 24th Presentation Available via Live Webcast
via COMTEX

June 20, 2003

WATERTOWN, Mass., Jun 20, 2003 (BUSINESS WIRE) --

OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) President and CEO Frederick Driscoll will discuss his Company`s strategy and review corporate and clinical development milestones in a presentation to investors and prospective partners at the BIO 2003 Annual Convention in Washington, D.C.

The presentation is scheduled to begin at 4:45 p.m. (ET) Tuesday, June 24 in Room C of the Washington Convention Center. A real-time Webcast of the presentation will be available by logging on to www.firstcallevents.com/service/ajwz382776179gf12.html.

BIO 2003 features 25 tracks of programming and sessions on policy, business development, science and regulatory affairs. More than 15,000 biotechnology industry executives, researchers, legislators, regulatory officials and journalists are expected to attend the conference, which runs from June 22-25.

About OXiGENE

OXiGENE is the world leader in the development of novel biopharmaceutical compounds called vascular targeting agents (VTAs), which are designed to block the flow of blood that supplies solid cancer tumors and other abnormal vasculature, while leaving healthy cells intact. The Company`s VTAs may have application in the treatment of certain forms of ocular disease and other conditions. OXiGENE`s lead VTA, Combretastatin A4 Prodrug, has advanced into Phase II and combination clinical trials in cancer patients in the United States and Europe. Three other OXiGENE VTAs, OXi4503, OXi6197 and OXi8007, are in pre-clinical development. For more information about OXiGENE, visit www.oxigene.com.

SOURCE: OXiGENE, Inc

Sharon Merrill Associates, Inc. David Calusdian (Investors), 617/542-5300 [e-mail] or Scott Solomon (Media), 617/542-5300 [e-mail]

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved.

JS200

[js200]

OXiGENE Invites Public to Listen to Second-quarter 2003 Financial Results Conference Call; Streaming audio of August 8 call will be available at www.oxigene.com
via COMTEX

July 21, 2003

WATERTOWN, Mass., Jul 21, 2003 (BUSINESS WIRE) --

OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), which is developing a novel class of tumor-starving compounds called vascular targeting agents (VTAs), invites the public to listen to a live audio Webcast of the Company`s second-quarter 2003 financial results conference call at 10:00 a.m. ET Friday, August 8, 2003. OXiGENE plans to announce its second-quarter financial results prior to the opening of the market on the same day. The call will be hosted by Fred Driscoll, OXiGENE`s president and CEO, and Dai Chaplin, Ph.D., chief scientific officer.

To listen to a live or an archived version of the Webcast, log on to the `Investor Center`section of the Company`s Web site, www.oxigene.com, and click on the link labeled `Presentations & Conference Calls.`

OXiGENE`s second-quarter conference call also can be heard live by dialing 888-214-7596 (domestic) or 415-537-1841 (international) five minutes prior to the call. A replay of the call will be available for 48 hours following the call. To access the replay, dial at 800-633-8284 (domestic) or 402-977-9140 (international) and refer to reservation number 21155054.

About OXiGENE

OXiGENE is the world leader in the development of novel biopharmaceutical compounds called vascular targeting agents (VTAs), which are designed to block the flow of blood that supplies solid cancer tumors and other abnormal vasculature, while leaving healthy cells intact. The Company`s VTAs may have application in the treatment of certain forms of ocular disease and other conditions. OXiGENE`s lead VTA, Combretastatin A4 Prodrug, has advanced into Phase II and combination clinical trials in cancer patients in the United States and Europe. Three other OXiGENE VTAs, OXi4503, OXi6197 and OXi8007, are in pre-clinical development. For more information about OXiGENE, visit www.oxigene.com.

SOURCE: OXiGENE, Inc.

Sharon Merrill Associates, Inc. David Calusdian (Investors) Scott Solomon (Media) 617/542-5300 [e-mail] [e-mail]

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved.


JS200

[robin05]

was ist mit oxygene los ?

sollte nicht eine rosige Zukunft bevorstehen ?

Igendwelche Infos, wie die Zahlen aussehen werden ?

[js200]

FDA Grants Orphan Drug Status to OXiGENE`s Combretastatin A4 Prodrug for Multiple Forms of Thyroid Cancer
via COMTEX

July 28, 2003

WATERTOWN, Mass., Jul 28, 2003 (BUSINESS WIRE) --

OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) announced today that, in response to the Company`s application, the U.S. Food and Drug Administration has awarded orphan drug status to OXiGENE`s Combretastatin A4 Prodrug (CA4P) for the treatment of anaplastic thyroid cancer (ATC). In addition, the FDA granted the orphan drug designation to CA4P for the treatment of medullary, Stage IV papillary and Stage IV follicular thyroid cancers. OXiGENE estimates that approximately 58,000 people in the United States currently have one of these four cancer sub-types.

CA4P is being tested in a Phase II clinical trial in patients with advanced ATC, one of four concurrent human oncology studies of the investigational drug.

`As we advance CA4P to market, the orphan drug designation - and the FDA fast track designation we announced last month - represent key building blocks in our clinical development and commercialization strategy,`said Fred Driscoll, OXiGENE`s president and CEO. `The FDA`s decision recognizes the potential for CA4P to be a cornerstone treatment not only for ATC but for other sub-types and stages of thyroid cancer, which would fill a significant unmet medical need.`

In the course of OXiGENE`s Phase I safety trials of CA4P, which were completed in 2001, one patient with ATC, who had exhausted all known treatment regimens used for this disease, responded completely to CA4P as a single-agent treatment. The patient has now been disease free for more than 44 months. One Phase I patient with medullary thyroid cancer experienced 17 months of disease stabilization, while a second medullary patient remained stable for one year.

`Thyroid tumors are known to be highly vascularized, and thus we believe they may be particularly susceptible to the blood-flow blocking effects triggered by vascular targeting compounds such as CA4P,`said Scott Young, OXiGENE`s Vice President of Clinical and Regulatory Affairs. `The FDA`s decision to broaden the orphan drug designation to include multiple forms of thyroid cancer provides OXiGENE with a strong incentive to evaluate the potential clinical development of CA4P in these other thyroid tumor types.`

Orphan drug designations are granted to provide economic incentives to stimulate the research, development and approval of promising products that treat rare diseases. The Orphan Drug Act guarantees seven years of market exclusivity to the first sponsor that obtains market approval for an orphan drug-designated product. It also provides tax credits to defray the cost of research conducted to generate the data required for marketing approval, funding to support clinical trials and assistance in designing research studies.

In June, CA4P received the FDA`s fast track designation for the treatment of anaplastic thyroid cancer. The fast track program is intended to facilitate the development and review of new drugs intended to treat life-threatening conditions for which there is no approved therapy.

A summary of the current clinical trials involving CA4P:

Clinical Trial Combination Indications----------------------------------------------------------------------Phase II single agent Anaplastic thyroid cancerPhase I/II radiotherapy Lung, head &neck and prostate cancerPhase I/II carboplatin and paclitaxel Ovarian cancerPhase Ib(1) carboplatin Various solid tumorsPhase I/II single agent Wet age-related macular degeneration----------------------------------------------------------------------(1) Patient enrollment has concluded
About OXiGENE

OXiGENE is the world leader in the development of novel biopharmaceutical compounds called vascular targeting agents (VTAs), which are designed to block the flow of blood that supplies solid cancer tumors and other abnormal vasculature, while leaving healthy cells intact. The Company`s VTAs may have application in the treatment of certain forms of ocular disease and other conditions. OXiGENE`s lead VTA, Combretastatin A4 Prodrug, has advanced into Phase II and combination clinical trials in cancer patients in the United States and Europe. Three other OXiGENE VTAs, OXi4503, OXi6197 and OXi8007, are in pre-clinical development. For more information about OXiGENE, visit www.oxigene.com.

Safe Harbor Statement

This news release contains `forward-looking statements`within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: OXiGENE`s ability to advance CA4P to market; the susceptibility of thyroid tumors to damage by CA4P; the ability of CA4P to be a cornerstone treatment for various stages or sub-types of thyroid cancer including ATC; the possibility that OXiGENE will pursue the potential benefits of CA4P as a treatment for a broad range of thyroid cancers; and the applicability of CA4P to certain forms of ocular disease. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to: the early stage of product development; the ability to secure necessary patents; uncertainties as to the future success of ongoing and planned clinical trials; and the unproven safety and efficacy of products under development. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements are contained in OXiGENE`s reports to the Securities and Exchange Commission, including OXiGENE`s 10-Q, 8-K and 10-K reports. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise.

SOURCE: OXiGENE, Inc.

Sharon Merrill Associates, Inc. David Calusdian (Investors), 617-542-5300 [e-mail] or Sharon Merrill Associates, Inc. Scott Solomon (Media), 617-542-5300 [e-mail]

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved.


JS200

[donnerpower]

Achtung!!!

Neue Daytrader Tipppp

BIOMIRA steht da_gegen erst am Anfang!!!

Kürzel:BIOM

Aktuell 1,34$





After a little research:

Consider: If all patients were stage IIIB and received optimal therapy(multiple rounds chemotherapy), fractionated radiotherapy and some receiving surgery; Now take the responders from this group-median survival time of 16 months. That is the best case scenario.

Consider: Patients in the current trial have received at least 1 course of chemotherapy and categorized as responders/stable and given 2 months of BLP25 at least.

Given the above: Projected median survival of 16.9 months at this December 2003.

But we know that the patients in this trial are both stage IIIb and IV.

The patients may have received more than one course of chemotherapy.

[js200]

Schaeffer`s Street Chatter Features Able Laboratories, OXiGENE, and Pixar: ABRX, OXGN, PIXR
via COMTEX

July 28, 2003

CINCINNATI, Jul 28, 2003 /PRNewswire via COMTEX/ --

Today`s Schaeffer`s Street Chatter features Able Laboratories (Nasdaq: ABRX), OXiGENE (Nasdaq: OXGN), and Pixar (Nasdaq: PIXR). A new daily feature available on SchaeffersResearch.com is Street Chatter. Every day, we`ll focus on three stocks that are generating a lot of attention on Internet message boards. We hope this will effectively offer information on equities that are popular in the investing world and will be a beneficial resource for our readers. For additional information about this report or to have it delivered to you free via email every day click on the following link. Each new subscriber will receive a FREE copy of Bernie Schaeffer`s Options 101 CD-ROM (a $49.95 value). http://www.schaeffersresearch.com/addinfo" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/addinfo .

(Logo: http://www.newscom.com/cgi-bin/prnh/20020725/SCHAEFFERLOGO ) Schaeffer`s Street Chatter: Able Laboratories

Able Laboratories (Nasdaq: ABRX) manufactures generic drugs, including a lower-priced substitute of Attention-Deficit-Disorder treatment Ritalin. Early this morning, the firm announced second-quarter earnings of 14 cents per share, two cents above Wall Street`s consensus estimate. Sales rose 51.6 percent in the second quarter to $18.9 million. Technically speaking, ABRX has enjoyed a solid uptrend for the past nine months, quadrupling in value since its September bottom. Throughout this time, the stock`s 10-week and 20- week moving averages have worked in tandem to support the shares. Options are not yet available on the security, but short sellers have taken an interest in the stock, as the number of shorted ABRX shares has been on the rise over the past six months and has increased month-over-month by at least 10 percent since March. This increase in bearish speculation is puzzling given the equity`s strong technical trend and its solid fundamental outlook. Wall Street is also hesitant to commit to the shares; according to Zacks, only three analysts follow the equity, two of whom list ABRX as a `hold.`

Click the following link to see a Weekly Chart of ABRX Since September 2002 With 10-Week and 20-Week Moving Averages: http://www.schaeffersresearch.com/wire?ID=8149" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=8149 .

OXiGENE

Biotechnology company OXiGENE (Nasdaq: OXGN) has rallied more than 60 percent today after the U.S. Food and Drug Administration gave `orphan drug` status to the firm`s new thyroid medication. Orphan drugs are provided with seven years of marketing exclusivity as well as other benefits. Additionally, the FDA said the company`s drug could potentially be used to treat up to four type of thyroid cancers, instead of just the one for which OXGN officials were targeting. Today`s strong rally in the shares has lifted OXGN back above its 10-day and 20-day moving averages for the first time since mid-June. On the sentiment front, Schaeffer`s put/call open interest ratio (SOIR) for the stock stands at 0.14, as there are nearly 6,000 open calls in the front three- months`series compared to under 1,000 open puts. This trend is continuing today, as options players scramble for a piece of the OXGN pie. Both the August and September series are seeing their fair share of call activity cross the tape in today`s session.

Click the following link to see a Daily Chart of OXGN since May 2003 With 10-Day and 20-Day Moving Averages: http://www.schaeffersresearch.com/wire?ID=8149" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=8149 .

Pixar

Pixar is the creative mastermind behind such box-office successes as Toy Story, Monsters Inc., and the unsinkable Finding Nemo. Over the weekend, the stock suffered a mixed review as part of an article in Barron`s. On the downside, some analysts feel as though PIXR is overpriced, trading at 18 times sales. Competition risks also remain, which could challenge the shares. On a more positive note, the firm recently agreed to a 50/50 revenue sharing plan with Walt Disney, which should be beneficial to PIXR`s future. The shares are trading slightly lower in today`s trading. After hitting a new all-time high earlier this month, the stock has since been consolidating into short-term support from its 10-day and 20-day moving averages. The shares are presently being squeezed between these two trendlines. On the options front, Schaeffer`s put/call open interest ratio (SOIR) for PIXR stands at 0.80, in the bottom 13 percent of all annual readings for this sentiment indicator. Although this points to a fair degree of optimism in the options crowd, the 11-percent increase in short interest suggests some lingering pessimistic sentiment. There are now more than 6.1 million PIXR shares sold short, amounting to a short-interest ratio of 5.4 times.

Click the following link to see a Daily Chart of PIXR since May 2003 with 10-Day and 20-Day Moving Averages: http://www.schaeffersresearch.com/wire?ID=8149" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/wire?ID=8149 .

The best way to take advantage of the timely Schaeffer commentaries is to sign up to receive their free e-newsletters - Opening View, Midday Report, Market Recap and Monday Morning Outlook. Click here to have the Schaeffer`s commentaries delivered to you free via email every day. Each new subscriber will receive a FREE copy of Bernie Schaeffer`s Options 101 CD-ROM (a $49.95 value). http://www.schaeffersresearch.com/addinfo" target="_blank" rel="nofollow ugc noopener">http://www.schaeffersresearch.com/addinfo .

About Schaeffer`s Investment Research ( www.SchaeffersResearch.com ):

Schaeffer`s Investment Research, founded by Bernie Schaeffer in 1981, is a diversified financial information and trading resources company with subscribers in over 110 countries. It publishes Bernie Schaeffer`s Option Advisor, the nation`s leading subscription newsletter devoted to options, as well as many other educational, bulletin and alert services. The firm`s website, www.SchaeffersResearch.com , is recognized as one of the leading information sources for stock and options traders and was cited as the top options website by both Forbes and Barron`s.

Contact: Tom Godich at Schaeffer`s, Phone: [phone]; Email: [e-mail]

SOURCE Schaeffer`s Investment Research

Tom Godich at Schaeffer`s, [phone], [e-mail] /Photo: http://www.newscom.com/cgi-bin/prnh/20020725/SCHAEFFERLOGO AP Archive: http://photoarchive.ap.org PRN Photo Desk, [phone] or [phone]

http://www.schaeffersresearch.com

Copyright (C) 2003 PR Newswire. All rights reserved.


JS200

[js200]

Last Trade: 13.270 Change: 5.220 (+64.845%)
Previous Close: 8.050 Volume: 14,698,300
Bid: 13.340 Ask: 13.250
Today`s Open: 12.498 # of Trades: 20,643

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


07/28/2003 (12:59 ET) Schaeffer`s Street Chatter Features Able Laboratories, OXiGENE, and Pixar: ABRX, OXGN, PIXR - PR Newswire



07/28/2003 (10:50 ET) Oxigene`s combretastatin A4 prodrug wins FDA `orphan drug` status in thyroid cancer - Datamonitor



07/28/2003 (09:47 ET) VOLUME(+): OXGN Volume 141% > 20-adsv, Stock +54.04% - Knobias



07/28/2003 (09:03 ET) OXGN Awarded Orphan Drug Status by FDA for Cancer Drug - Knobias



07/28/2003 (08:38 ET) PREMARKET: OXGN Gets Orphan Drug Status for CA4P - Knobias



07/28/2003 (07:03 ET) FDA Grants Orphan Drug Status to OXiGENE`s Combretastatin A4 Prodrug for Multiple Forms of Thyroid Cancer - Hugin AS



07/28/2003 (07:01 ET) FDA Grants Orphan Drug Status to OXiGENE`s Combretastatin A4 Prodrug for Multiple Forms of Thyroid Cancer - Business Wire



07/24/2003 (15:20 ET) OXGN: Short Interest UP 4.1% to 2.6M in Jul 2003 - Knobias



07/22/2003 (15:39 ET) Pacific Exchange to Trade 22 New Options - PR Newswire



07/21/2003 (10:53 ET) BIOTECHNOLOGY: Lehman Keeps Positive View on Industry - Knobias



07/21/2003 (08:43 ET) OXiGENE Invites Public to Listen to Second-quarter 2003 Financial Results Conference Call - Hugin AS



07/21/2003 (08:25 ET) OXiGENE Invites Public to Listen to Second-quarter 2003 Financial Results Conference Call; Streaming audio of August 8 call will be available at www.oxigene.com - Business Wire



07/08/2003 (12:23 ET) JP Morgan Affirms Strong Sales Growth for Cancer Drugs - Knobias



07/03/2003 (09:31 ET) Oxigene launches ophthalmic study at Johns Hopkins University - Datamonitor



07/02/2003 (14:03 ET) Oxigene surges on news of Combretastatin trial launch - AFX News Asia



07/02/2003 (14:03 ET) Oxigene surges on news of Combretastatin trial launch - AFX News Europe



07/02/2003 (14:03 ET) Oxigene surges on news of Combretastatin trial launch - AFX News UK



07/02/2003 (12:49 ET) Goldman Maintains Neutral View on Biotech Industry - Knobias



07/02/2003 (09:36 ET) Biotech shares on the increase at Swedish online brokers - report - M2 Communications



07/02/2003 (08:57 ET) OXGN Announces Phase I/II Clinical Trials to Begin - Knobias



07/02/2003 (07:15 ET) OXiGENE Announces Launch of Ophthalmic Clinical Trial at The Johns Hopkins University School of Medicine - Hugin AS



07/02/2003 (07:00 ET) OXiGENE Announces Launch of Ophthalmic Clinical Trial at The Johns Hopkins University School of Medicine - Business Wire



07/01/2003 (15:57 ET) SECTOR(HCR): FDA Says It`s Committed to Enforcements - Knobias



07/01/2003 (11:49 ET) SECTOR(HCR): Biotechs Down, Led by MLNM - Knobias



07/01/2003 (11:32 ET) CONF: OXGN To Present At Anti-Cancer Drug Conference @ 14:10 ET - Knobias


JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


07/29/2003 (10:29 ET) VOLUME(-): OXGN Volume 13% > 20-adsv, Stock -10.45% - Knobias



07/29/2003 (09:02 ET) Wall Street News Alert: Stocks to Watch! - Internet Wire



07/29/2003 (07:01 ET) MEDIA: Today`s IBD Mentions OXGN - Knobias



07/29/2003 (06:09 ET) MEDIA: Today`s Wall Street Journal Mentions OXGN - Knobias



07/28/2003 (18:57 ET) Oxigene, ISTA, HealthTronics and more - UPDATE 4 - AFX News Asia



07/28/2003 (18:57 ET) Oxigene, ISTA, HealthTronics and more - UPDATE 4 - AFX News Europe



07/28/2003 (18:57 ET) Oxigene, ISTA, HealthTronics and more - UPDATE 4 - AFX News UK



07/28/2003 (15:29 ET) FDA Gives `Orphan` Status to Experimental Cancer Treatment - Knight Ridder



07/28/2003 (14:00 ET) BIOTECHS: Industry Rallies on OXGN, HGSI, XOMA, IMCL - Knobias



07/28/2003 (12:59 ET) Schaeffer`s Street Chatter Features Able Laboratories, OXiGENE, and Pixar: ABRX, OXGN, PIXR - PR Newswire



07/28/2003 (10:50 ET) Oxigene`s combretastatin A4 prodrug wins FDA `orphan drug` status in thyroid cancer - Datamonitor



07/28/2003 (09:47 ET) VOLUME(+): OXGN Volume 141% > 20-adsv, Stock +54.04% - Knobias



07/28/2003 (09:03 ET) OXGN Awarded Orphan Drug Status by FDA for Cancer Drug - Knobias



07/28/2003 (08:38 ET) PREMARKET: OXGN Gets Orphan Drug Status for CA4P - Knobias



07/28/2003 (07:03 ET) FDA Grants Orphan Drug Status to OXiGENE`s Combretastatin A4 Prodrug for Multiple Forms of Thyroid Cancer - Hugin AS



07/28/2003 (07:01 ET) FDA Grants Orphan Drug Status to OXiGENE`s Combretastatin A4 Prodrug for Multiple Forms of Thyroid Cancer - Business Wire



JS200

[js200]

Animal Studies Demonstrate OXiGENE`s CA4P Suppresses Development and Induces Regression of Ocular Neovascularization
via COMTEX

July 31, 2003

WATERTOWN, Mass., Jul 31, 2003 (BUSINESS WIRE) --

OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced the results of independent animal studies demonstrating the potential role of the Company`s lead compound, Combretastatin A4 Prodrug (CA4P), in preventing and treating certain retinal degenerative diseases. Findings of the study are published in the current issue of the peer-reviewed journal Investigative Ophthalmology and Visual Science (IOVS).

The studies were conducted at The Johns Hopkins University School of Medicine by a team of researchers including Peter A. Campochiaro, M.D., a professor of ophthalmology at the school`s renowned Wilmer Eye Institute. Dr. Campochiaro and Assistant Professor of Ophthalmology Quan Dong Nguyen, M.D. are leading the current Phase I/II clinical trial of CA4P in patients with wet age-related macular degeneration, known as wet AMD. Between 2 million and 3 million people in the United States have significant vision loss caused by wet AMD.

`The pre-clinical research produced by Dr. Campochiaro and his colleagues, as well as several other pre-clinical ophthalmic models using CA4P, provided the impetus for OXiGENE to move CA4P into human trials at Johns Hopkins,`said Fred Driscoll, OXiGENE`s president and CEO. `We are very pleased that Dr. Campochiaro considered the data from this study compelling enough to take CA4P into trials at one of the world`s leading research institutions.`

The study was designed to gauge CA4P`s ability to suppress the development of choroidal neovascularization (CNV), a condition in which aberrant blood vessels beneath the retina leak blood and fluid into the retina. CNV is the primary cause of severe vision loss in patients with retinal degenerative diseases such as wet AMD. Researchers conducted experiments using transgenic mice with CNV caused by an over expression of vascular endothelial growth factor in the retina (rho/VEGF mice) and mice with laser-induced rupture of Bruch`s membrane.

In both groups of mice, daily intraperitoneal injections of CA4P resulted in a `significant reduction`in CNV. Dr. Campochiaro and his colleagues concluded, `In this study, we have demonstrated that a tubulin-binding agent, CA-4-P, suppresses the development of subretinal neovascularization in rhodopsin/VEGF transgenic mice and suppresses the development of CNV at Bruch`s membrane rupture sites. This suggests that when administered before onset of an angiogenic stimulus, CA-4-P can prevent these two forms of ocular neovascularization. A recent study has shown that CA-4-P can also prevent ischemia-induced retinal neovascularization in mice. Therefore, CA-4-P joins a growing list of drugs that have potential as prophylactic agents for retinal and/or choroidal neovascularization. However, CA-4-P also caused partial regression of established CNV, a finding that sets it apart from other drugs. To our knowledge, intraocular gene transfer of pigment epithelium-derived factor (PEDF) is the only other gene-therapy-based or drug treatment that has been shown conclusively to cause partial regression of CNV, and therefore CA-4-P is in select company. Therefore, similar to PEDF gene transfer, treatment with CA-4-P has potential for treatment of established CNV.`

The Johns Hopkins trial is the first human study of OXiGENE`s lead compound in a non-life-threatening indication. CA4P also is being studied in four late-stage cancer trials in five indications including anaplastic thyroid cancer, ovarian cancer and malignancies of the lung, head &neck and prostate.

About OXiGENE

OXiGENE is the world leader in the development of novel biopharmaceutical compounds called vascular targeting agents (VTAs), which are designed to block the flow of blood that supplies solid cancer tumors and other abnormal vasculature, while leaving healthy cells intact. OXiGENE`s lead VTA, Combretastatin A4 Prodrug, has advanced into Phase II and combination clinical trials in cancer patients in the United States and Europe. The investigational compound also is being evaluated in an ophthalmic study in patients with wet age-related macular degeneration. Three other OXiGENE VTAs, OXi4503, OXi6197 and OXi8007, are in pre-clinical development. For more information about OXiGENE, visit www.oxigene.com.

Safe Harbor Statement

This news release contains `forward-looking statements`within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: the potential for CA4P to block development and promote regression of ocular neovascularization. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to: the early stage of product development; the ability to secure necessary patents; uncertainties as to the future success of ongoing and planned clinical trials; and the unproven safety and efficacy of products under development. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements are contained in OXiGENE`s reports to the Securities and Exchange Commission, including OXiGENE`s 10-Q, 8-K and 10-K reports. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise.

SOURCE: OXiGENE, Inc.

Sharon Merrill Associates, Inc. (Investors) David Calusdian, 617-542-5300 [e-mail] or Sharon Merrill Associates, Inc. (Media) Scott Solomon, 617-542-5300 [e-mail]

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire. All rights reserved.


JS200